Chasing BMS, J&J files BCMA CAR-T for multiple myeloma to FDA

Chasing BMS, J&J files BCMA CAR-T for multiple myeloma to FDA

Source: 
Pharmaforum
snippet: 

Johnson & Johnson’s Janssen unit has filed a rolling submission for its multiple myeloma CAR-T ciltacabtagene autoleucel (cilta-cel) to the FDA, in hot pursuit of Bristol-Myers Squibb’s delayed rival therapy.